NEOGEN CORP is 1.3x more valuable than Anbio Biotechnology by market capitalization ($2.01 B vs $1.50 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NEOG | NNNN |
|---|---|---|
| Market cap | $2.01 B | $1.50 B |
| US-listed rank | #2096 | #2317 |
| Revenue (latest FY) | $894.66M | $8.65M |
| Net income (latest FY) | -$1.09B | $6.40M |
| Net margin | -122.1% | 74.1% |
| P/E (trailing FY) | - | 234.2 |
| SEC filings | 1,896 | 40 |
NEOGEN CORP is 1.3x more valuable than Anbio Biotechnology by market capitalization ($2.01 B vs $1.50 B).
In their latest fiscal years, NEOGEN CORP reported $894.66M in revenue while Anbio Biotechnology reported $8.65M.
Full pages: NEOGEN CORP and Anbio Biotechnology, or browse the full rankings.